Zacks Research Has Negative Estimate for IRWD Q2 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Zacks Research reduced their Q2 2026 earnings estimates for shares of Ironwood Pharmaceuticals in a research note issued to investors on Tuesday, April 21st. Zacks Research analyst Team now expects that the biotechnology company will earn $0.26 per share for the quarter, down from their previous forecast of $0.27. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.88 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q3 2026 earnings at $0.30 EPS, FY2026 earnings at $0.88 EPS, Q1 2027 earnings at $0.03 EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.04) EPS and FY2028 earnings at $0.10 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%.The business had revenue of $47.71 million for the quarter, compared to analysts’ expectations of $86.10 million.

Other analysts also recently issued reports about the company. Wells Fargo & Company upped their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the company an “equal weight” rating in a research note on Monday, January 5th. Craig Hallum raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Jefferies Financial Group restated a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Wall Street Zen lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Citizens Jmp boosted their price objective on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Stock Down 9.3%

NASDAQ IRWD opened at $3.79 on Thursday. Ironwood Pharmaceuticals has a 52-week low of $0.53 and a 52-week high of $5.78. The business’s 50-day moving average price is $3.71 and its 200 day moving average price is $3.45. The firm has a market cap of $618.00 million, a P/E ratio of 29.15 and a beta of 0.17.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Alexander J. Denner sold 6,730,800 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the completion of the sale, the director owned 9,188,635 shares of the company’s stock, valued at approximately $28,025,336.75. This trade represents a 42.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.70% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in IRWD. Integrated Wealth Concepts LLC grew its position in Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,406 shares during the period. LSV Asset Management acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth approximately $30,000. Captrust Financial Advisors purchased a new position in Ironwood Pharmaceuticals in the 2nd quarter valued at approximately $32,000. Jump Financial LLC purchased a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $34,000. Finally, DGS Capital Management LLC acquired a new position in Ironwood Pharmaceuticals during the fourth quarter worth $35,000.

Key Headlines Impacting Ironwood Pharmaceuticals

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood will present LANDMARK survey findings on HCP perspectives about TPN burden in short bowel syndrome at Digestive Disease Week (May 2–5). This raises clinical and commercial visibility for Ironwood’s GI/rare-disease franchise and could support longer-term investor sentiment. BusinessWire: DDW Presentation
• Neutral Sentiment: Zacks Research made several mixed estimate changes — raising a few quarter forecasts (e.g., Q1/Q2 2027 and Q4 2026) while issuing a “Hold” rating, indicating cautious but not bearish analyst positioning.
• Neutral Sentiment: Third‑party coverage comparing Ironwood to peers is circulating; such comparative analyses can influence investor positioning but are not company-specific catalysts. Financial Comparison
• Negative Sentiment: Zacks cut several near-term estimates (including Q2 2026, Q3 2026, Q3 2027 and FY2026 from $0.98 to $0.88), reflecting reduced near-term revenue/earnings expectations — a key driver pressuring the stock today.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.